Background: We determined qualitative and quantitative serum unconjugated bile acid (SUBA) levels among children with history of intestinal failure (IF) and suspected small bowel bacterial overgrowth (SBBO). Methods: This was a single-center, case-control pilot study conducted at Cincinnati Children's Hospital Medical Center. Children with history of IF and suspected SBBO were enrolled as subjects. Age-matched children without IF or suspected SBBO served as controls. All participants underwent small bowel fluid sampling for microbial culture analysis. Additionally, serum fractionated and total bile acids were measured by liquid chromatography-mass spectrometry at enrollment and following treatment for SBBO. 
invasive testing and empirically treat with antimicrobials, sometimes in a continuous monthly cycle. Less invasive and more reliable methods for diagnosing bacterial overgrowth in this population are needed. This study provides a framework for further investigation to determine the potential utility of serum unconjugated bile acids for the diagnosis of
Introduction
Small bowel bacterial overgrowth (SBBO), defined as the presence of >10 5 colony-forming units (CFU) of colonic type bacterial flora/mL of sampled duodenal fluid, 1 is commonly encountered in children with short bowel syndrome and intestinal failure (IF). 2, 3 SBBO can lead to diarrhea, abdominal distension, feeding intolerance, nutrient malabsorption, D-lactic acidosis, elevated serum ethanol levels, and/or hyperammonemia. [4] [5] [6] Furthermore, SBBO may increase risk of central line infections. 7, 8 Currently, the "gold standard" for the diagnosis of SBBO is quantification of CFU present in a duodenal aspirate. This method of diagnosis is invasive, expensive, and requires sedation or general anesthesia with pediatric endoscopy, rendering this diagnostic tool clinically impractical. Other, less invasive methods of diagnosing SBBO, such as breath tests and urine tests, have varying sensitivity, specificity, and lack standardization, making them problematic. 1, 9 As a result, the accurate diagnosis and management of SBBO in infants and children remains a challenge.
Serum unconjugated bile acid (SUBA) measurement may provide an alternative method to diagnose SBBO in children with IF since overgrowth leads to deconjugation of bile acids in the proximal intestine with reabsorption and appearance of unconjugated bile acids in the peripheral circulation. [10] [11] [12] Although elevated SUBA have been welldescribed in adults with SBBO, [13] [14] [15] [16] [17] we have yet to identify any studies demonstrating the diagnostic value and clinical utility of this method in the pediatric population. This pilot study was designed to determine if SUBA concentrations were increased in children with a history of IF and suspected of having SBBO (study subjects) compared with healthy controls (age-matched children without IF or symptoms suggestive of SBBO). We also sought to determine if antimicrobial treatment of SBBO would impact SUBA concentrations in children with history of IF. 
Materials and Methods

Enrollment
This was a prospective, case-control pilot study performed at Cincinnati Children's Hospital Medical Center (CCHMC) between October 2014 and August 2015. After obtaining informed consent from parents/guardians, IF subjects and controls age 9 months-17 years were enrolled in the study. Additional assent was required from IF subjects/controls >11 years per institutional review board guidelines. Inclusion criteria for IF subjects were: 1) planned upper endoscopy for clinical indications (i.e., abdominal pain, dysphagia, vomiting, and eosinophilic esophagitis); 2) history of extensive intestinal resection resulting in impaired nutrient absorption and a need for either parenteral or supplementary non-oral enteric feeding; and 3) clinical suspicion for SBBO defined only by the presence of symptoms (not quantified) exceeding subject's baseline (abdominal pain, abdominal distension, feeding intolerance, excessive stooling, excessive ostomy output, emesis). Exclusion criteria included: 1) current febrile illness; 2) antibiotic use within 14 days of enrollment; 3) cholestatic liver disease (direct bilirubin >1 mg/dL); 4) history of organ transplantation; or 5) parent refusal. Control group inclusion criteria included: 1) planned upper endoscopy for diagnostic evaluation, and 2) age-matched to within 6 months of study subjects. Exclusion criteria included: 1) current febrile illness; 2) antibiotic use within 14 days of enrollment; 3) history of intestinal resection; 4) current diarrheal illness; 5) diagnosis of irritable bowel syndrome; 6) presence of any chronic medical condition; 7) history of parenteral nutrition (PN) requirement; and 8) parent refusal.
Procedures
Enrolled IF subjects and controls underwent small bowel aspirate and fasting-blood collections. All sample collection was performed on the day of scheduled upper endoscopy. IF subjects found to have SBBO by small bowel aspirate (>10 5 CFU/mL of cultured fluid) had a repeat blood sample collected within 1 week after completion of antimicrobial treatment for SBBO during the study period. Antimicrobial treatment was not controlled for in this study, with agent, dose, and frequency determined by primary provider. No further research participation was required for controls. For all IF subjects, a thorough chart review was performed to collect the following data: age (months), diagnoses, intestinal length (cm), medications, antibiotic exposures, probiotic exposures, recent lab results (6 months), and feeding modality (enteral versus [vs] parenteral). Additionally, all IF subjects and controls were assessed for presence of symptoms, including diarrhea, ostomy output, abdominal distension, feeding intolerance, fussiness, abdominal pain, emesis, fever, and flatulence, on the day of procedures and following treatment (in IF subjects).
Intestinal Aspirate
Aspirates were collected in the following manner. After endoscope was positioned in the distal duodenum (second and third anatomical segments), a sterile catheter was passed via endoscope with subsequent intraluminal aspiration of 2 mL fluid by hand, with care being taken to avoid aeration of the sample. The fluid sample was analyzed for pH (acidic fluid samples, pH <7, may inhibit growth of bacterial cultures). Fluid samples with pH ࣙ7 were considered adequate and then placed in 2 separate sterile 1.5-mL microcentrifuge tubes for analysis in the Clinical Laboratory Improvement Amendments (CLIA)-certified CCHMC Microbiology Laboratory. Fluid samples were cultured for aerobic and anaerobic bacteria and colony counts. Positive aspirates for SBBO were defined by colony counts of >10 5 CFU/mL. Identification of predominant genera and species of bacteria was performed on all positive aspirates using matrix-assisted laser desorption ionizationtime of flight mass spectrometer.
Serum Bile Acid Measurement
Serum collected after induction of anesthesia was analyzed for total bile acid concentration, qualitative distribution of 15 different unconjugated and conjugated bile acids using a validated liquid chromatography-mass spectrometry (LC-MS)/MS method. 18 Proportion measurements for SUBA and chenodeoxycholic acid (CDCA) were taken as a percent of total bile acid concentration measured in each research participant. Serum was analyzed from subjects with IF and confirmed SBBO within 1 week of completion of an antimicrobial course. All samples were collected following a minimum 4-hour fast.
Data Analysis
The study was powered to determine differences in total SUBA between IF subjects with SBBO and controls. Power analysis for a 2-group independent sample t-test performed prior to study initiation indicated that a sample size of 8 in each group would be sufficient to attain a power of 0.8 with an α of 5% to detect an expected difference in total SUBA concentrations between controls and IF subjects with SBBO (control mean of 1.2 μmol/L vs subject mean of 10 μmol/L) based upon previous studies in adults.
14 Therefore, a sample size of 10 in each group was selected to determine correlations between study variables. Variables analyzed included total SUBA concentrations (μM), total bile acid concentrations, and individual conjugated and unconjugated bile acid concentrations. Statistical analysis was performed using SAS R software (SAS Institute Inc., 2013, version 9.4, Cary, NC). Exact Wilcoxon 2-sample test was used to compare control vs cases. To compare outcomes pretreatment and post-treatment and between age-matched cases and controls, Wilcoxon rank-sum test was used. Statistical significance was based on a P-value of <0.05 
Antibiotic exposure is defined as cycled antibiotic use monthly prior to enrollment (subjects) and use within 3 weeks of enrollment (controls). EoE, eosinophilic esophagitis; GERD, gastroesophageal reflux disease; OEIS, omphalocele, extrophy of bladder/rectum, imperforate anus, spinal defects; PN, total parenteral nutrition; PPI, proton pump inhibitor.
Results
Demographics
Fourteen subjects with history of IF were enrolled in the study between October 2014 and August 2015 ( Table  1 ). The median age was 57 months. The most common diagnoses for IF among subjects at study enrollment were complicated gastroschisis and congenital intestinal atresias (58%). Other diagnoses included necrotizing enterocolitis, cloacal extrophy (OEIS syndrome), midgut volvulus, and Hirschsprung's disease. Regarding intestinal anatomy, the majority of IF subjects had a history of both small bowel and large bowel resections (8 of 14) . Additionally, the small and large intestine were in continuity in the majority (12 of 14). The ileocecal valve was present in 3 subjects (21%), and 5 (36%) were receiving PN at the time of study. Approximately one third of subjects (36%) had received a regimen of cycled antibiotics (defined as 1-2 weeks of use monthly) for prevention of SBBO in the months prior to enrollment (chart review went back 6 months prior to enrollment), while 6 (43%) were using enteral proton pump inhibitors (PPI) at time of enrollment. Only 2 subjects were receiving probiotics (Lactobacillus acidophilus, Lactobacillus rhamnosus GG) prior to enrollment. Symptoms of SBBO reported at time of enrollment (exceeding subject's baseline) were abdominal pain, abdominal distension, and feeding intolerance (defined as excessive stooling and/or emesis with feeding advancement). Eleven controls were enrolled in the study ( Table 1 ). The median age was 54 months, and the most common diagnosis among controls was eosinophilic esophagitis (n = 5, 46%), followed by gastroesophageal reflux disease, dysphagia, and emesis. Only 1 control subject had antibiotic exposure during the month prior to study enrollment, while PPI use was common (73%). The most prevalent symptoms among controls in the week preceding enrollment were abdominal pain, emesis, and diarrhea. SUBA concentrations were also compared as a fraction of total serum bile acids measured in each cohort and found to be present in greater proportion among IF subjects (median 87.4%, range 29.7%-92.6%) compared with controls (median 22.2%, range 9.2%-42.5%, P = 0.002; Table  1 ). Several individual bile acids also differed significantly between IF subjects and controls. Free CDCA was present in higher proportions in IF subjects (median 40%, range 0%-56.6%) compared with controls (median 0%, range 0%-2.1%, P = 0.004), while glycodeoxycholic acid (GCDCA) was less prevalent among IF subjects (median 6.1%, range 3.8%-24.6%) compared with controls (median 35.4%, range 23.5%-51.1%, P = 0.042).
Bile acid profile comparisons among subjects with history of IF. Additional bile acid comparisons were made among 
SUBA following treatment for positive-aspirate SBBO.
Among the 6 IF subjects who underwent antimicrobial treatment for duodenal aspirate-proven SBBO, 4 provided post-treatment samples. Monotherapy was used to treat SBBO in 5 of 6 subjects with 1 of the following: ciprofloxacin, rifaximin, trimethoprim-sulfamethoxazole, amoxicillin-clavulanate, or colistin. The remaining subject was treated concurrently with trimethoprimsulfamethoxazole and amoxicillin-clavulanate. There was no significant difference in total serum bile acids, SUBA, SUBA percentage, or serum CDCA acid concentrations between pretreatment and post-treatment samples among subjects with aspirate-proven SBBO (Table 2) .
Organisms cultured for SBBO. Aspirates for SBBO were positive in 6 subjects with history of IF ( Table 3) . Half of these subjects received cycled antibiotics for SBBO prior to study enrollment (1 on a combination of ciprofloxacin/ polymixin E alternating 2 weeks each, monthly; the other 2 on metronidazole for 2 weeks each month). The majority of aspirates (5 of 6), grew both gram-positive and gramnegative bacteria. The final aspirate was comprised of only gram-negative organisms. Genera of gram-positive organisms cultured were Lactobacillus, Bifidobacterium, Enterococcus, Streptococcus, and Gemella, while Veillonella, Morganella, Klebsiella, and Escherichia comprised the gram-negative genera cultured. Enterococcus and Klebsiella were the predominant genera cultured among all aspirates. Duodenal aspirates for both IF subjects receiving probiotics prior to enrollment were negative for bacterial overgrowth.
Discussion
Our study showed that SUBA were significantly increased in children with history of IF and suspected SBBO compared with control children with disease in both concentration and proportion of bile acids measured. Additionally, CDCA was the most predominant SUBA identified among children with history of IF and suspected SBBO. IF subjects with positive aspirates for SBBO had a higher concentration of CDCA compared with IF subjects with negative aspirates. Treatment of positive aspirates for SBBO during the study period did not alter SUBA concentration or proportion of bile acids measured. Elevated SUBA has been previously reported in adults with SBBO and is attributed to increased intestinal bacterial deconjugation of intraluminal bile acids in the presence of SBBO. Bolt et al found elevated postprandial SUBA concentrations in adults with SBBO diagnosed by [ 14 C] glycocholate breath test.
14 Additionally, Masclee et al found SUBA to be elevated in adults with SBBO diagnosed by jejunal fluid aspirate. 15 The majority (8 of 10) had SUBA concentrations >4 μM/L. In contrast, none of the controls without SBBO had SUBA concentrations above this value. Therefore, Masclee et al proposed that a threshold SUBA level of 4 μM/L would be a clinically useful marker for the diagnosis of SBBO in adults.
Bile acid profiles for SBBO in children have not previously been described. However, norms for serum bile acid measurements in healthy children have been described. Niijima described normal serum bile acid measurements in 98 healthy children using high-performance liquid chromatography. In 98 children, aged 4-6 years, the mean total serum bile acid concentration was 3.68 ± 1.57 μM/L, with a mean SUBA concentration of 0.53 ± 0.36 μM/L. 19 SUBA were found to comprise approximately 16.33% ± 9.79% of the bile acids analyzed in healthy children. 19 In previous unpublished work using LC-MS methodology, we observed that healthy children had a mean concentration of overall bile acid <8 μM/L. The mean fraction of SUBA among bile acids measured was found to be approximately 18%.
When we compare our results to these previously determined thresholds, we see that the proportion of SUBA in our controls (22%) does approximate the expected value of 18% in healthy children, whereas children with history of IF and suspected SBBO had a much higher of fraction of SUBA at 87%. Absolute concentration of SUBA was higher as well in IF subjects compared with controls but only 5 of 14 IF subjects exceeded the proposed cutoff of 4 μM/L for SBBO described in adults by Masclee et al 15 (1 of 11 controls did surpass 4 μM/L). Among these 5 IF subjects, however, 4 did have positive aspirates for SBBO. Therefore, as an attempt to determine if bile acid changes observed were due to the presence of SBBO vs the IF itself, we determined to exclude controls and analyze bile acid profiles among IF subjects only, comparing those with positive aspirates to those with negative aspirates for SBBO.
In this comparison, IF subjects with positive aspirates were found to have higher absolute concentrations of total bile acids measured and CDCA without difference in relative proportion. The majority of IF subjects with positive aspirates for SBBO (4 of 6) did exceed the proposed SUBA cutoff of 4 μM/L for SBBO. However, proportions of SUBA were comparable between IF subjects with and without positive aspirates. Therefore, it is possible that the difference in concentration of SUBA among IF subjects is attributable to the total bile acid pool measured, which was almost 10 times higher in the positive aspirate group, and not the presence of SBBO. Possible explanations for the increased bile acids measured in subjects with positive aspirates may be attributed to alterations in fat absorption patterns and the enterohepatic circulation process, which can be influenced by age differences and anatomic variations, both of which were present among IF subjects in this study.
CDCA, 1 of the main primary bile acids synthesized by the liver, was found in greater concentration and proportion among IF subjects suspected of SBBO compared with controls. This observation remained unchanged when comparing IF subjects with positive and negative aspirates for SBBO. It is possible that these differences are attributable to the global increased bile acid concentration measured in patients with SBBO. Other possibilities include alterations in the interaction between intraluminal bile acids, farnesoid X receptor, Takeda G protein-coupled receptor 5, and downstream effects driven by changes to intestinal anatomy, the intestinal microbiome, and nutrition delivery, which has been described in animals. 20 Gut microbiota are able to execute modification of bile acids and deconjugation through the use of bile salt hydrolases. Bile salt hydrolase activity has been identified among various phyla of intestinal flora in humans, namely, Firmicutes, Bacteroidetes, and Actinobacteria. 21, 22 With the exception of 1 aspirate, all of the bacteria identified in positive SBBO aspirates (Lactobacillus, Bifidobacterium, Enterococcus, Streptococcus, and Escherichia) belong to these phyla, which may explain the differences in SUBA concentrations measured. We acknowledge the inherent challenges and limitations with obtaining small bowel aspirates through duodenal sampling for SBBO, such as the preference for more distal aspirates (jejunal) when possible and difficulty with yield of bacterial colonies in both aerobic and anaerobic laboratory environments. Furthermore, we recognize that bacterial species cultured from the proximal small bowel do not always correspond to the flora present distally in the intestinal lumen.
Although there was subjective improvement clinically following treatment for SBBO among IF subjects with positive aspirates, SUBA concentrations did not decrease as would be expected. This may be due to the use of antimicrobials that did not target the correct flora responsible for SBBO and the deconjugation of bile acids. Other possibilities include small sample size and, finally, the possibility that the presence of large intestinal resections may contribute to increase SUBA among IF subjects. As an exploratory aim, we analyzed SUBA concentrations with respect to exposure to cycled antibiotics prior to enrollment. There was a significant difference in median SUBA concentrations (data not shown). This is particularly interesting given that metronidazole, used most often in a monthly cycling regimen, targets anaerobes, which are primarily attributed to the development of SBBO. 23, 24 Among the 5 IF subjects with cycled antibiotic exposure, 3 had positive aspirates, although all had elevated SUBA. Given the small number of IF subjects being compared, it is difficult to draw any definitive conclusions. It is possible that prior exposure to prophylactic antibiotic use in a cyclic pattern leads to dysbiosis in the gut microbial community, which may alter the balance of microbes that are able to deconjugate luminal bile acids. We have previously published some of these possible influences. 8, 25 The synthesis, regulation, and enterohepatic recycling of bile acids is a complex process that relies partially on multiple anatomic checkpoints, liver function, gut microbiota composition, and available receptors. 22, 26 Furthermore, intestinal resection (namely, of the ileum) does not appear to have the same effect on bile acid synthesis in children as has been found in adults. 27 In this study we hypothesized that SUBA concentration would be able to distinguish pediatric subjects with history of IF and SBBO from those who did not. We chose to enroll pediatric IF subjects with symptoms suggestive of SBBO rather than confirmed SBBO due to frequency of SBBO in this population. We acknowledge the inherent bias with respect to the subject population due to possible alterations in bile acid levels that may already be present secondary to anatomy. Although we controlled for the presence of liver disease in study subjects, the study cohort of IF subjects was inherently heterogeneous with respect to anatomy, exposure to cycled antibiotics, and PN dependence, all of which may influence bile acid physiology and serve as potential confounders to our study results. Additionally, the initial power calculation for our study required 8 subjects in each group for comparison. However, we were only able to identify 6 subjects with culture proven SBBO. Therefore, these study results are limited in their interpretation.
Conclusions
In this pilot study, SUBA concentrations vary among pediatric IF subjects with suspected SBBO in comparison with non-IF children. However, follow-up studies are needed that include various types of pediatric subjects with aspirate-proven SBBO to confirm that SUBA elevation coincides with SBBO and not just pediatric IF. Additionally, larger, more longitudinal studies are needed to establish bile acid profiles in children with IF at baseline and during SBBO to categorize these profiles based on variations in anatomy and microbiome patterns and verify the clinical utility of SUBA measurements for SBBO in this population.
